NCT02316522View on ClinicalTrials.gov

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

CompletedOBSERVATIONAL

Enrollment

158

Participants

Timeline

Start Date

October 23, 2014

Primary Completion Date

April 9, 2018

Study Completion Date

April 9, 2018

Conditions

Type 2 Diabetes

Trial Locations (1)

Unknown

Hamad Medical Corporation, Doha

Sponsors

Collaborators (1)

Hamad Medical Corporation

All Listed Sponsors

collaborator

Hamad Medical Corporation

INDUSTRY

collaborator

Weill Cornell Medical College in Qatar

OTHER

lead

Weill Medical College of Cornell University

OTHER